Consequently, pharmacological targeting of HDACs has emerged as an important therapeutic area of research, with the discovery of HDAC inhibitors for the treatment of cancers such as leukaemias and myelodysplastic disorders [11], as well as Alzheimer’s disease [12], Huntington’s disease [13], muscular atrophy [14] and Friedrich’s ataxia [15]. This evidence concerns the gene HDAC9 and early-onset autosomal dominant Alzheimer disease.